SCHEMBL24955640

SCHEMBL24955640

Cn1cc(-c2ccccc2)nc1C#Cc1nc(N2CCOCC2)c2ncn(C)c2n1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.47
NOS1 P29475 1/20 0.41
PDE10A Q9Y233 4/20 0.41
KDM4E B2RXH2 9/20 0.39
ALDH1A1 P00352 9/20 0.39
HPGD P15428 8/20 0.39
HSD17B10 Q99714 8/20 0.39
CYP3A4 P08684 5/20 0.39
LRRK2 Q5S007 1/20 0.39
PIK3R1 P27986 1/20 0.39
TSHR P16473 2/20 0.38
CASP1 P29466 1/20 0.38
ADORA1 P30542 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPT P10636 1/20 0.37
MTOR P42345 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24955833 0.90 PIK3CA (0.46) PIK3CAPDE10AALDH1A1LRRK2PIK3R1
SCHEMBL30202390 0.86 PDE10A (0.38) PIK3CAPDE10ALRRK2ADORA1
SCHEMBL30203054 0.86 CNR2 (0.38) PIK3CAPDE10AADORA1
SCHEMBL24955686 0.86 PDE10A (0.38) PIK3CAPDE10ALRRK2ADORA1
SCHEMBL30202248 0.86 MTOR (0.49) PIK3CAPDE10AMTOR
SCHEMBL30202168 0.86 MTOR (0.49) PIK3CAPDE10AMTOR
SCHEMBL24955629 0.84 PIK3CA (0.39) PIK3CANOS1PDE10AKDM4EALDH1A1
SCHEMBL24955681 0.83 PIK3CA (0.46) PIK3CANOS1PDE10AKDM4EALDH1A1
SCHEMBL24955834 0.82 MEN1 (0.43) PIK3CAPDE10AALDH1A1ADORA1SMN1; SMN2
SCHEMBL30202224 0.81 PIK3CA (0.37) PIK3CAPDE10AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023007185-A1 IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE Benevolentai Cambridge Limited (GB) 2023-02-02 WO disclosed